Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0043 in Moderate to Severe Acne Vulgaris
NCT07449156Phase 2Not yet recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HB0043 in acne vulgaris, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
HB0043
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT07449156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449156.